<DOC>
	<DOCNO>NCT00423514</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy , clofarabine , melphalan , thiotepa , donor stem cell transplant help stop growth cancer abnormal cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving tacrolimus mycophenolate mofetil transplant may stop happen . PURPOSE : This phase I/II trial study side effect best dose clofarabine give together melphalan thiotepa , follow donor stem cell transplant see well work treat patient high-risk and/or advance hematologic cancer disease .</brief_summary>
	<brief_title>Clofarabine , Melphalan , Thiotepa Followed By Donor Stem Cell Transplant Treating Patients With High-Risk and/or Advanced Hematologic Cancer Other Disease</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose clofarabine administer melphalan thiotepa follow allogeneic stem cell transplantation patient high-risk and/or advance hematologic malignancy . ( Phase I ) - Determine 1-year disease-free survival patient treat regimen . ( Phase II ) - Determine efficacy regimen , term antileukemic potential relapse rate , patient . Secondary - Evaluate incidence severity nonhematologic toxicity regimen patient . - Evaluate incidence severity graft-versus-host disease patient treat regimen . OUTLINE : This phase I , dose-escalation study clofarabine follow open-label , phase II study . Patients stratify accord HLA-compatible donor type ( related v unrelated ) . - Cytoreductive therapy : Patients receive clofarabine IV 2 hour daily day -9 -5 , thiotepa IV 4 hour day -4 , melphalan IV 30 minute daily day -3 -2 . Cohorts 3-6 patient receive escalate dos clofarabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients undergo bone marrow peripheral blood stem cell transplantation receive tacrolimus IV continuously 24 hour orally every 8-12 hour begin day -3 methotrexate IV day 1 , 3 , 6 , 11 . Patients undergo UCB transplantation receive tacrolimus IV continuously 24 hour orally every 8-12 hour begin day -3 mycophenolate mofetil ( MMF ) IV orally 2 3 time daily day -3 45 followed taper day 100 ( unless sign acute GVHD ) . Patients undergo UCB transplantation without GVHD continue tacrolimus 6 month follow taper discontinue 1 year transplantation . - Allogeneic hematopoietic stem cell transplantation ( HSCT ) allogeneic umbilical cord blood ( UCB ) transplantation : Patients undergo allogeneic HSCT ( bone marrow peripheral blood stem cell ) double UCB transplantation day 0 . Patients also receive filgrastim ( G-CSF ) IV subcutaneously begin day 7 continue blood count recover . - Maintenance therapy : Approximately 2 month transplantation patient ALL , M4 M5 AML , transplant AML bone marrow relapse receive cytarabine intrathecally ( IT ) monthly 5 dos . Patients history CNS leukemia receive cytarabine IT monthly month 2-12 HSCT . After completion study therapy , patient follow periodically least 4 year . PROJECTED ACCRUAL : A total 42 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm diagnosis 1 following : Acute myelogenous leukemia , meet 1 follow criterion : In first complete remission ( CR ) , meet 1 follow criterion : Poor risk [ ( 15,17 ) , inv 16 , ( 8,21 ) ] Not candidate total body irradiation ( TBI ) Any infant first CR In second CR , meet follow criterion : All patient In second CR OR relapsed/refractory disease , meet follow criterion : All patient Blast percentage &gt; 5 % &lt; 25 % bone marrow ( BM ) time stem cell transplantation ( SCT ) Acute lymphoblastic leukemia , meet 1 follow criterion : In first CR , meet 1 follow criterion : Poor risk [ ( 9 ; 22 ) , ( 4 ; 11 ) AND CR 728 day induction ] Not candidate TBI Any infant first CR In second CR , meet follow criterion : All patient In second CR OR relapsed/refractory disease , meet follow criterion : All patient Blast percentage &gt; 5 % &lt; 25 % BM time SCT Acute undifferentiated biphenotypic leukemia , meet follow criterion : All patient Blast percentage &gt; 5 % &lt; 25 % BM time SCT Chronic myelogenous leukemia , meet follow criterion : All patient In first chronic phase Myelodysplastic syndrome , meet 1 follow criterion : Primary high risk disease Stage &gt; RAEB1 Secondary high risk disease All patient Any stage Juvenile myelomonocytic leukemia All patient No double peripheral blast count within period 2 week No active CNS disease HLAcompatible donor available meeting 1 follow criterion : Related donor Genotypically phenotypically match ≥ 7 8 HLAA , B , C DRB1 allele Unrelated donor meeting 1 follow criterion : 8 8 allele match For patient &lt; 18 year old : 7 8 allele match mismatch 1 HLAA , B , C , DRB1 allele Two HLAcompatible unrelated cord blood ( UCB ) unit available meeting follow criterion : HLAmatched minimally 4 6 HLAA , HLAB , DRB1 allele HLAA HLAB match intermediate resolution molecular technique DRB1 allele match high resolution molecular technique Both match UCB unit cryopreserved nucleated cell dose ≥ 1.5 x 10^7/kg PATIENT CHARACTERISTICS : Karnofsky OR Lansky performance status 70100 % SGOT &lt; 2 time upper limit normal Bilirubin &lt; 1.5 mg/dL ( unless liver disease involvement ) Creatinine normal OR creatinine clearance &gt; 60 mL/min LVEF &gt; 50 % rest OR shorten fraction ≥ 29 % Patients asymptomatic pulmonary disease prior risk factor OR symptomatic pulmonary disease diffusion capacity &gt; 50 % predict ( correct hemoglobin ) eligible No active uncontrolled viral , bacterial , fungal infection No known HIV I II positivity No known human Tcell lymphotrophic virus I II positivity Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No hydroxyurea within past 2 week No allogeneic autologous stem cell transplantation within past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>